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Background: Micrometastases in bone marrow of women with early breast cancer were first identified immunocytochemically in
the 1980s. We report on the original cohort of women with a median follow-up of 30 years.
Patients and Methods: In total, 350 women with primary breast cancer had eight bone marrow aspirates examined with antibody
to epithelial membrane antigen. Data on long-term mortality were obtained via record linkage to death certification.
Results: At a 30-year median follow-up, 79 out of 89 (89%) patients with micrometastases have died compared with 202 out of 261
(77%) without (hazard ratio¼ 1.46 (95% CI 1.12–1.90), P¼ 0.0043). Most marked effect of micrometastases on overall survival (OS)
was seen in patients aged p50 at surgery (N¼ 97, P¼ 0.012), and on all patients within 10 years of diagnosis. In multivariable
analyses, the presence of micrometastases was no longer a statistically significant prognostic factor.
Conclusions: Bone marrow micrometastases are predictive for OS, particularly in the first decade and in younger patients.
The identification by our laboratory of micrometastatic disease in
the bone marrow of women with early breast cancer, using
immunocytochemical techniques, first generated considerable
interest in 1980 (Sloane et al, 1980). Initial reports indicated that
the presence of these tumour cells, in the absence of disease
elsewhere, predicted for a poor outcome (Mansi et al, 1987,
1991, 1999).
Over the years, many groups have evaluated different
antibodies, different techniques and examined large cohorts of
patients in an attempt to further define the importance of these
cells. Two meta-analyses of bone marrow micrometastases (BMM)
have been reported. The first in 1998 where BMM were identified
in 35% of patients and appeared to be an independent predictor of
poor survival in two of the studies, but not overall (Funke and
Schraut, 1998). The second meta-analysis in 2005 identified BMM
in 31% of patients, and was an independent predictor for inferior
overall survival (OS) (Braun et al, 2005).
Our group initially reported outcomes for this cohort of 350
patients in 1991 and subsequently in 1999 with a 6- and 12.5-year
median follow-up, respectively. We now report outcomes after a
median of 30 years representing the longest follow-up using this
technique to analyse BMM.
MATERIALS AND METHODS
Patients and methods. Study procedures and ethics approval
have been described previously (Mansi et al, 1991). After written
consent, each patient was screened for metastatic disease. At the
time of surgery, B2mls of bone marrow was aspirated from eight
sites and was prepared and stained as described previously by using
a polyclonal antibody to epithelial membrane antigen (Dearnaley
et al, 1983).
Follow-up. Patients were reviewed as described previously (Mansi
et al, 1991), with a 3 monthly clinical examination and blood test, a
6 monthly bone scan and annual chest X-ray for 5 years. At relapse
all patients were fully staged to detect disease at other sites.
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Most patients were discharged after 5-year follow-up. Details of
outcome were obtained from hospital records and/or general
practitioner. The mortality status of all patients within the study
was flagged by the HSCIC. The causes of death were coded
according to the International Classification of Diseases (versions
8–10) from the death certificates provided. No relapse data were
sought after 1995.
Statistical analysis. Survival was calculated from date of surgery
to death from any cause (OS) or from breast cancer-specific
survival (BCSS) as written on the death certificate. Because of the
lack of consistent relapse data after 1995, relapse-free survival
results are not reported in this manuscript.
Kaplan–Meier curves were plotted and survival of patients with
and without BMM was compared by the log-rank test. Cox PH
modelling with reported hazard ratios (HRs; with 95% CIs)
investigated the effect of BMM on OS and BCSS, both univariately
and after adjusting for other prognostic factors (tumour size, ER
status, lymph nodes, vascular invasion, adjuvant treatment and age
at surgery). The effect of BMM on OS was also assessed in age-
specific subgroups of p50, 51–70 and 470 years. P-value o0.05
was considered statistically significant.
Proportional hazard assumptions determining whether any
difference in OS or BCSS between patients with and without BMM
are constant overtime was tested using Schoenfeld residuals.
RESULTS
The cohort comprised 350 women, median age at surgery of 59
years (range 26–85). BMM were identified in 25% (89 out of 350)
of patients at the time of primary surgery. The presence or absence
of BMM in relation to a number of prognostic factors has been
published previously (Supplementary Table 1).
Adjuvant treatment. Adjuvant therapy was given to 141 (40%)
patients according to the various protocols available at that time
and without knowledge of the patient’s BMM status.
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Figure 1. Kaplan–Meier estimates of overall survival in patients, by
presence of micrometastases.
Table 1. Unadjusted and adjusted models for overall survival
Unadjusted Adjusted
N Deaths % HR 95% CI P-value HR 95% CI P-value
Micrometastases
Negativea 261 202 77.4 1 – – 1 – –
Positive 89 79 88.8 1.46 1.12–1.90 0.005 1.29 0.98–1.71 0.070
Tumour size (cm)
o2a 108 75 69.4 1 – – 1 – –
2–5 205 174 84.9 1.80 1.37–2.36 o0.001 1.43 1.07–1.90 0.014
45 15 15 100.0 3.37 1.93–5.90 o0.001 2.26 1.24–4.11 0.007
Unknown 22 17 77.3 1.44 0.85–2.44 0.18 1.13 0.65–1.93 0.67
ER status
Positivea 224 190 84.8 1 – – 1 – –
Negative 108 77 71.3 0.72 0.55–0.94 0.02 0.85 0.62–1.15 0.29
Unknown 18 14 77.8 0.73 0.42–1.26 0.26 1.00 0.57–1.75 0.99
Number of lymph nodes involved
0a 170 123 72.4 1 – – 1 – –
1–3 100 86 86.0 1.60 1.21–2.11 0.001 1.33 0.98–1.80 0.070
4–9 41 36 87.8 1.97 1.36–2.86 o0.001 1.73 1.13–2.64 0.011
X10 9 9 100.0 6.83 3.43–13.61 o0.001 3.99 1.93–8.24 o0.001
Unknown 30 27 90.0 1.97 1.29–2.99 0.002 1.25 0.80–1.96 0.33
Vascular invasion
Absenta 208 160 76.9 1 – – 1 – –
Present 142 121 85.2 1.50 1.18–1.90 0.001 1.10 0.85–1.43 0.48
Adjuvant treatment
Nonea,b 214 181 84.6 – – – 1 – –
Endocrinec 102 80 78.4 0.93 0.71–1.21 0.58 0.93 0.70–1.25 0.63
Cytotoxicd 34 20 58.8 0.61 0.38–0.97 0.04 1.15 0.68–1.94 0.60
Age at primary surgery – – – 1.04 1.03–1.06 o0.001 1.04 1.02–1.05 o0.001
Abbreviations: CI¼ confidence interval; CMF¼ cyclophosphamide, methotrexate, 5-fluorouracil; ER¼oestrogen receptor; HR¼hazard ratio.
aReference group.
bIncludes 22 patients who received placebo as part of a trial (Coombes et al, 1987), and 5 patients whose treatment was given as other but no further details known.
cIncludes patients who received aminoglutethimide (n¼ 33) and tamoxifen (n¼ 69).
dAll patients received CMF.
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Overall survival. After a median follow-up of 30 years
(IQR 28  6–30  7), 281 (80%) patients are known to have died.
OS was inferior in those women with BMM at the time of
primary surgery: 79 out of 89 vs 202 out of 261 (HR¼ 1.46 (95% CI
1.12–1.90), P¼ 0.0043, Figure 1).
The most marked effect of BMM on OS was seen in patients
aged p50 at surgery (N¼ 97, P¼ 0.012) and those aged 51–70
(N¼ 191, P¼ 0.022), with less of a difference seen in those aged
470 (N¼ 62, P¼ 0.60) (Supplementary Figures 1 and 2).
In univariate analyses of OS, the following characteristics, large
tumour size, ER-negative status, receipt of cytotoxic adjuvant
treatment, presence of involved lymph nodes and vascular invasion
at primary surgery, were all statistically significant poor prognostic
factors (Table 1). After inclusion in an adjusted multivariable
model, only tumour size and lymph node involvement remained
statistically significant.
Breast cancer-specific survival. Breast cancer was one of the
stated causes of death for 51out of 89 (57%) and 115 out of
261 (44%) of patients with and without BMM, respectively.
The proportion of the total number of deaths classified as due to
breast cancer decreased in later years of follow-up (Supplementary
Table 2). Notably, of the 52 breast cancer deaths in patients with
BMM, 44 (85%) occurred within the first 10 years after primary
surgery compared with 81 out of 116 (70%) in patients who did not
have BMM.
Breast cancer-specific survival was inferior in those with BMM
univariately HR¼ 1.67 (95% CI 1.20–2.32), P¼ 0.002 (Table 2),
but did not retain independent prognostic significance in multi-
variable analyses with this duration of follow-up.
The most marked effect of BMM on BCSS was seen in patients
agedp50 at surgery (P¼ 0.029) and those aged 51–70 (P¼ 0.029)
and with less of a difference seen in those aged 470 (P¼ 0.44).
CONCLUSION
Our results indicate that BMM predict for a poorer OS even after
30 years of follow-up. With longer follow-up, we have shown that
this is most significant in the younger age groups and within 10
years of primary surgery. After this time, especially in older
women, the test is no longer predictive for survival because women
die from other conditions. That most of the impact of BMM is in
the first 10 years in this study may be a consequence of the fact that
the majority of women (209 out of 350) did not receive adjuvant
cytotoxic chemotherapy, even in the younger age group.
Although from 1980 to 1987 our group was the sole group to
describe BMM and their prognostic significance, many others have
since studied this phenomenon as reflected in the meta-analysis
published in 2005 (Braun et al, 2005). Results from other groups
have not all consistently shown prognostic significance with BMM.
We are unclear why this is the case (Salvadori et al, 1990;
Courtemache et al, 1991).
In previous publications we have already discussed that our
antibody to epithelial membrane antigen would not now be
considered to be the best marker of tumour cells. The use of
Table 2. Unadjusted and adjusted models for breast cancer-specific survival
Unadjusted Adjusted
N
BCSS
events % HR 95% CI P-value HR 95% CI P-value
Micrometastases
Negativea 261 116 44.4 1 – – 1 – –
Positive 89 52 58.4 1.67 1.20–2  32 0.002 1.23 0.87–175 0.25
Tumour size (cm)
o2a 108 33 30.6 1 – – 1 – –
2–5 205 113 55.1 2.48 1.68–3.67 o0.001 2.27 1.52–3.38 o0.001
45 15 13 86.7 5.59 2.93–10.66 o0.001 3.66 1.82–7.39 0.001
Unknown 22 9 40.9 1.68 0.81–3.52 0.17 1.26 0.59–2.68 0.56
ER status
Positivea 224 109 48.7 1 – – 1 – –
Negative 108 52 48.1 0.92 0.68–1.30 0.62 0.89 0.61–1.31 0.57
Unknown 18 7 38.9 0.68 0.37–1.57 0.32 1.08 0.48–2.43 0.85
Number of lymph nodes involved
0a 170 55 32.4 1 – – 1 – –
1–3 100 60 60.0 2.39 1.66–3.45 o0.001 1.89 1.26–2.84 0.002
4–9 41 31 75.6 3.46 2.22–5.39 o0.001 3.07 1.86–5.06 o0.001
X10 9 6 66.7 8.25 3.51–19.38 o0.001 7.58 3.07–18.73 o0.001
Unknown 30 16 53.3 2.35 1.34–4  10 0.003 1.91 1.05–3.45 0.03
Vascular invasion
Absenta 208 79 38.0 1 – – 1 – –
Present 142 89 62.7 2.14 1.58–2.91 o0.001 1.40 1.00–1.95 0.05
Adjuvant treatment
Nonea,b 214 96 44.9 1 – – 1 – –
Endocrinec 102 55 53.9 1.18 0.85–1.65 0.32 0.96 0.66–1.38 0.81
Cytotoxicd 34 17 50.0 1.06 0.63–1.78 0.82 1.23 0.68–2.22 0.49
Age at primary surgery – – – 1.01 1.00–1.02 0.084 1.00 0.98–1.01 0.79
Abbreviations: BCSS¼breast cancer-specific survival; CI¼ confidence interval; CMF¼ cyclophosphamide, methotrexate and 5-fluorouracil; ER¼oestrogen receptor; HR¼hazard ratio.
aReference group.
bIncludes 22 patients who received placebo as part of a trial (Coombes et al, 1987), and 5 patients whose treatment was given as other but no further details known.
cIncludes patients who received aminoglutethimide (n¼ 33) and tamoxifen (n¼ 69).
dAll patients received CMF.
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different antibodies or combinations of antibodies or different
techniques such as PCR-based molecular assays has been the
subject of continuing research over the past two decades (Salvadori
et al, 1990; Courtemache et al, 1991; Braun et al, 2000; Becker et al,
2004; Body et al, 2006; Fehm et al, 2006).
A number of groups have looked at the comparison of BMM
and circulating tumour cells in the peripheral blood using different
methods for detection and, in particular, Slade et al (2009) studied
the comparison as a means of providing information on early
relapse by repeated sampling after primary surgery. These, and
subsequent studies show that patients at high risk are more likely
to show the continued presence of both BMM and circulating
tumour cells during follow-up, even 12 years after diagnosis (Payne
et al, 2012a). The same group of patients had circulating cell-free
DNA with similar characteristics to the primary breast cancer even
12 years after diagnosis, despite there being no evidence of overt
metastatic disease thus implying dormancy of such cells (Shaw
et al, 2012). The concept of dormancy has been further explored by
Payne et al (2012b) who showed that the presence of circulating
tumour cells in the bone marrow was inversely related to
circulating-free DNA in the plasma. Interestingly, Nadal et al
(2012) suggested that if circulating tumour cells differ genetically
from the primary tumour, this may explain the variability in
response to the treatment and outcome.
With the focus now being on circulating tumour cells,
recent studies in early breast cancer have shown that their
presence does predict for a poorer outcome (Pierga et al, 2008;
Lucci et al, 2012; Rack et al, 2014). Current guidelines for the
American Society of Clinical Oncology do not recommend
that the presence of circulating tumour cells be used to inform
the decision-making on adjuvant therapy, although the most
recent edition of the American Joint Commission on Cancer
Staging Manual does include a new category of cM0(iþ ) to
identify such women who have microscopic disease in the blood
or bone marrow (American Joint Commission on Cancer
Staging, 2010).
The initial detection of BMM in women with early breast cancer
over three decades ago set in motion a large number of studies
using a variety of techniques. Our understanding of molecular
markers, methods of detection of minimal disease and the concept
of dormancy has improved substantially over the years; further-
more, bone marrow aspiration has largely been superseded by
detecting and characterising circulating tumour cells and circulat-
ing cell-free DNA.
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